BSX Quote, Financials, Valuation and Earnings

Integer Holdings has a net margin of 14.45% compared to Boston Scientific's net margin of -5.14%. Boston Scientific's return on equity of 9.57% beat Integer Holdings's return on equity of 4.85%.

Boston Scientific has a consensus price target of $116.12, signalling upside risk potential of 12.89%. On the other hand Integer Holdings has an analysts' consensus of $147.88 which suggests that it could grow by 24.85%. Given that Integer Holdings has higher upside potential than Boston Scientific, analysts believe Integer Holdings is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.685, which suggesting that the stock is 31.536% less volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.7B, which are larger than Integer Holdings quarterly revenues of $437.4M. Boston Scientific's net income of $674M is higher than Integer Holdings's net income of -$22.5M. Notably, Boston Scientific's price-to-earnings ratio is 75.08x while Integer Holdings's PE ratio is 56.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.72x versus 2.39x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 14.45% compared to Boston Scientific's net margin of -45.89%. Boston Scientific's return on equity of 9.57% beat Masimo's return on equity of -39.91%.

Boston Scientific has a consensus price target of $116.12, signalling upside risk potential of 12.89%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 16.29%. Given that Masimo has higher upside potential than Boston Scientific, analysts believe Masimo is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.685, which suggesting that the stock is 31.536% less volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.7B, which are larger than Masimo quarterly revenues of $372M. Boston Scientific's net income of $674M is higher than Masimo's net income of -$170.7M. Notably, Boston Scientific's price-to-earnings ratio is 75.08x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.72x versus 4.30x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 14.45% compared to Boston Scientific's net margin of 28.26%. Boston Scientific's return on equity of 9.57% beat ResMed's return on equity of 25.76%.

Boston Scientific has a consensus price target of $116.12, signalling upside risk potential of 12.89%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 7.94%. Given that Boston Scientific has higher upside potential than ResMed, analysts believe Boston Scientific is more attractive than ResMed.

Boston Scientific has a beta of 0.685, which suggesting that the stock is 31.536% less volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Boston Scientific pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.7B, which are larger than ResMed quarterly revenues of $1.3B. Boston Scientific's net income of $674M is higher than ResMed's net income of $365M. Notably, Boston Scientific's price-to-earnings ratio is 75.08x while ResMed's PE ratio is 27.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.72x versus 7.20x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 14.45% compared to Boston Scientific's net margin of 11.15%. Boston Scientific's return on equity of 9.57% beat Stryker's return on equity of 14.2%.

Boston Scientific has a consensus price target of $116.12, signalling upside risk potential of 12.89%. On the other hand Stryker has an analysts' consensus of $423.98 which suggests that it could grow by 11.31%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

Boston Scientific has a beta of 0.685, which suggesting that the stock is 31.536% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.091%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.86% to investors and pays a quarterly dividend of $0.84 per share. Boston Scientific pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.7B, which are smaller than Stryker quarterly revenues of $5.9B. Boston Scientific's net income of $674M is higher than Stryker's net income of $654M. Notably, Boston Scientific's price-to-earnings ratio is 75.08x while Stryker's PE ratio is 51.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.72x versus 6.33x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.